Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2020

01-07-2020 | Cytostatic Therapy | Hepatobiliary Tumors

Adjuvant Chemotherapy in Resected Biliary Tract Cancer

Author: John N. Primrose

Published in: Annals of Surgical Oncology | Issue 7/2020

Login to get access

Excerpt

For many years, biliary tract cancer was something of a ‘Cinderella’ malignancy. It appeared highly lethal, presented late, the surgery was difficult with high levels of morbidity, and there was little pharma interest as it was a less common cancer. Before the last decade, there were no definitive reports on the use of chemotherapy that could be used to guide the management of patients with any confidence. The only adjuvant trial of note covered pancreatic cancer as well as all biliary cancer,1 and, although it showed some potential in gallbladder cancer, the chemotherapy schedule was not one that is presently used. …
Literature
1.
Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–1695.CrossRef
2.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.CrossRef
3.
Primrose JN, Fox R, Stubbs, C, Neoptolemos J, Garden OJ, Valle J, et al., for the BILCAP Study Group. Adjuvant capecitabine for resected biliary tract cancer. The BILCAP randomised trial. Lancet Oncol. 2019;35:663–673.CrossRef
4.
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ting Ma Y, Arora A, et al: ABC-06|A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC + mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy [abstract no. 4003]. J Clin Oncol. 2019;37(15 Suppl).
5.
Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.CrossRef
6.
Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658–667.CrossRef
7.
Nakachi K, Konishi M, Ikeda M, Mizusawa J, Eba J, Okusaka T, et al., on behalf of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. A randomized phase III trial of adjuvant S-1 therapy vs observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48(4):392–395.CrossRef
8.
Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial): a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.CrossRef
9.
Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.CrossRef
10.
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–1027.CrossRef
11.
Metadata
Title
Adjuvant Chemotherapy in Resected Biliary Tract Cancer
Author
John N. Primrose
Publication date
01-07-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08537-z

Other articles of this Issue 7/2020

Annals of Surgical Oncology 7/2020 Go to the issue

Hepatobiliary Tumors

Phase 2 Trial of Adjuvant Chemotherapy With S − 1 for Node-Positive Biliary Tract Cancer (N-SOG 09)

Hepatobiliary Tumors

Laparoscopic Versus Open Thermal Ablation of Colorectal Liver Metastases: A Propensity Score-Based Analysis of Local Control of the Ablated Tumors

Health Services Research and Global Oncology

Local versus Radical Excision of Early Distal Rectal Cancers: A National Cancer Database Analysis

Breast Oncology

Residual Glandular Breast Tissue After Mastectomy: A Systematic Review

Breast Oncology

Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants

ASO Author Reflections

ASO Author Reflections: Clinical Significance of Peripheral Blood Inflammatory Markers in Thymic Epithelial Tumors